We have located links that may give you full text access.
A comprehensive approach for evaluating charge heterogeneity in biosimilars.
European Journal of Pharmaceutical Sciences 2018 March 31
Charge heterogeneity is often evaluated during biosimilar development as it is a universal feature of monoclonal antibodies (mAbs). A common approach in the industry is to develop a biosimilar product with a similar overall charge profile as the reference product. However, uncertainty remains with this approach as the same charge profile in two different products may be caused by different mechanisms. In this work, we present a comprehensive investigation of the charge variants of a therapeutic monoclonal antibody and its biosimilar candidate. Not only did the candidate show a similar charge profile as the reference product, our studies revealed that the same factors contributed to the charge variants of the reference product and the biosimilar candidate. We believe our cause-based approach mitigates the risks associated with the profile-based method and is a rational approach for the charge evaluation of biosimilars.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app